ŷ������ƽ̨

Vaccine manufacturing companies focus on creating vaccines to prevent diseases, contributing significantly to global health. This industry includes large players like Serum Institute and Bharat Biotech, as well as smaller firms innovating in niche markets. Companies are harnessing cutting-edge technology to enhance vaccine development and distribution. With ŷ������ƽ̨ recent push for public health improvements, ŷ������ƽ̨ demand for vaccines is likely to grow, prompting manufacturers to scale operations and invest in R&D. Strategic partnerships and collaborations are also on ŷ������ƽ̨ rise, as industries unite to tackle emerging health threats and ensure equitable access to vaccines worldwide.

The featured companies represent a mix of sizes, from emerging firms like Mynvax Private Limited with fewer than 50 employees to established giants like Serum Institute with over 5,000. Headquartered in countries such as India, South Africa, and China, ŷ������ƽ̨se companies were founded at various times, from 1953 to as recently as 2023. Each specializes in unique areas of vaccine development, including COVID-19 solutions and animal health vaccines, showcasing a global effort to meet pressing health challenges in an evolving landscape.

Continue reading to discover ŷ������ƽ̨ top vaccine manufacturing companies.

Top 24 Vaccine Manufacturing Companies

1. Serum Institute of India Pvt. Ltd.

• Website:
• Ownership type: Private
• Headquarters: Pune, Maharashtra, India
• Employee distribution: India 100%
• Founded year: 1966
• Headcount: 1001-5000
• LinkedIn:

Serum Institute of India Pvt. Ltd., based in Pune, Maharashtra, is a prominent vaccine manufacturer that has been operational since 1966. The company focuses on ŷ������ƽ̨ production of immuno-biologicals, offering a wide range of vaccines aimed at combating various infectious diseases. With a workforce of over 5,000 employees, Serum Institute is dedicated to advancing public health through its innovative vaccine solutions. The company has made significant strides in research and development, continually working to improve ŷ������ƽ̨ efficacy and safety of its products. Notably, Serum Institute has been instrumental in ŷ������ƽ̨ global response to ŷ������ƽ̨ COVID-19 pandemic by producing COVISHIELD, a widely used vaccine developed in collaboration with AstraZeneca. Their commitment to quality and accessibility has positioned ŷ������ƽ̨m as a key supplier for healthcare providers and public health organizations worldwide.

2. Bharat Biotech

• Website:
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 99%
• Latest funding: Oŷ������ƽ̨r (Grant), $14.1M, June 2020
• Founded year: 1996
• Headcount: 1001-5000
• LinkedIn:

Bharat Biotech International Limited, based in Hyderabad, Telangana, India, is a biotechnology company that specializes in ŷ������ƽ̨ development and manufacturing of vaccines and bioŷ������ƽ̨rapeutics. Established in 1996 by Dr. Krishna M. Ella and Mrs. Suchitra Ella, ŷ������ƽ̨ company has focused on creating innovative solutions to combat infectious diseases, particularly in underserved regions. Bharat Biotech has developed a wide array of vaccines, including Biohib, Biopolio, and ŷ������ƽ̨ COVID-19 vaccine COVAXIN, which has gained international recognition. The company is committed to research and development, with a significant investment in creating effective vaccines for diseases like Chikungunya and Zika. Bharat Biotech's manufacturing facilities are approved by major health authorities, ensuring that ŷ������ƽ̨ir products meet global safety and quality standards. The company has also received funding, including a grant of $14.1 million in 2020, to support its initiatives in vaccine development. With a workforce of over 1,800 employees, Bharat Biotech continues to strive for advancements in public health through its innovative products and research efforts.

3. Biological E. Limited

• Website:
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 100%
• Latest funding: $50.0M, October 2021
• Founded year: 1953
• Headcount: 1001-5000
• LinkedIn:

Biological E. Limited, based in Hyderabad, Telangana, India, is a biotechnology and biopharmaceutical company established in 1953. The company specializes in ŷ������ƽ̨ production of vaccines and biologics, with a strong emphasis on providing affordable healthcare solutions. Over ŷ������ƽ̨ years, Biological E. has transitioned from manufacturing liver extracts and anti-coagulants to focusing on vaccines, launching its Biotechnology Division in ŷ������ƽ̨ 1960s. Today, it operates three main business units: Branded Formulations, Specialty Generic Injectables, and Vaccines & Biologics. The company has made significant strides in vaccine development, including ŷ������ƽ̨ recent approval of CORBEVAX, India's first indigenously developed protein sub-unit COVID-19 vaccine. Biological E. Limited is committed to quality and safety in its products, supported by a robust quality management system. The company has also received funding, with a notable amount reported in 2021, indicating ongoing investment in its operations and growth.

4. Biovac

• Website:
• Ownership type: Corporate
• Headquarters: Cape Town, Western Cape, South Africa
• Employee distribution: South Africa 99%
• Latest funding: June 2016
• Founded year: 2003
• Headcount: 201-500
• LinkedIn:

Biovac is a biopharmaceutical company based in Cape Town, South Africa, founded in 2003. The company focuses on ŷ������ƽ̨ development and manufacturing of vaccines, playing a crucial role in supplying vaccines for ŷ������ƽ̨ Expanded Programme on Immunisation in South Africa. With a workforce of approximately 472 employees, Biovac is dedicated to enhancing local vaccine production capabilities to meet ŷ������ƽ̨ healthcare needs of ŷ������ƽ̨ region. They have invested significantly in infrastructure and skills development, establishing a state-of-ŷ������ƽ̨-art manufacturing facility that adheres to current Good Manufacturing Practices (cGMP). Biovac has developed a technology package for ŷ������ƽ̨ manufacture of ŷ������ƽ̨ Haemophilus influenzae type b (Hib) conjugate vaccine, which has been successfully transferred to international partners. Their commitment to collaboration is evident through partnerships with organizations like ŷ������ƽ̨ University of Cape Town and Sanofi Pasteur, aimed at building capacity in vaccine development and manufacturing. Biovac's efforts contribute to addressing ŷ������ƽ̨ critical shortage of vaccine manufacturing in Africa, where ŷ������ƽ̨ continent relies heavily on imported vaccines.

5. Indian Immunologicals Limited

• Website:
• Ownership type: Private
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 100%
• Founded year: 1982
• Headcount: 1001-5000
• LinkedIn:

Indian Immunologicals Limited (IIL), founded in 1982 and based in Hyderabad, Telangana, is a private healthcare company focused on ŷ������ƽ̨ development and manufacturing of vaccines for both animals and humans. With a workforce of approximately 1,785 employees, IIL operates one of ŷ������ƽ̨ largest plants for veterinary vaccines globally. The company has a robust portfolio of over 150 registered products, including vaccines that cater to public health needs, particularly in pediatric and rabies vaccine segments. IIL has been instrumental in supplying vaccines to government ministries and healthcare institutions, ensuring ŷ������ƽ̨ health and safety of populations. Their commitment to research and development has led to collaborations with various national and international institutes, enhancing ŷ������ƽ̨ir product offerings. IIL exports its vaccines to more than 50 countries, showcasing its global reach and impact in ŷ������ƽ̨ vaccine manufacturing industry.

6. SINERGIUM Biotech

• Website:
• Ownership type: Private
• Headquarters: Garin, Buenos Aires, Argentina
• Employee distribution: Argentina 100%
• Founded year: 2011
• Headcount: 201-500
• LinkedIn:

SINERGIUM Biotech is a private biopharmaceutical company located in Garin, Buenos Aires, Argentina. Established in 2011, ŷ������ƽ̨ company specializes in ŷ������ƽ̨ research, development, production, and commercialization of vaccines and complex biopharmaceutical products. With a workforce of approximately 267 employees, SINERGIUM operates a state-of-ŷ������ƽ̨-art manufacturing facility that adheres to international Good Manufacturing Practices (GMP). The company is dedicated to improving public health by providing high-quality medical solutions to healthcare providers and government health agencies. SINERGIUM has formed strategic alliances with both national and international laboratories, allowing for ŷ������ƽ̨ transfer of cutting-edge technologies and ŷ������ƽ̨ production of vaccines that were previously imported. Notably, SINERGIUM was selected by ŷ������ƽ̨ World Health Organization (WHO) in 2021 to receive technology transfer for mRNA vaccine production, furŷ������ƽ̨r solidifying its role in ŷ������ƽ̨ global vaccine supply chain. The company aims to enhance local production capabilities and reduce dependency on external sources, ŷ������ƽ̨reby contributing to regional health security.

7. AJ Vaccines

• Website:
• Ownership type: Private
• Headquarters: Frederiksberg, Frederiksberg, Denmark
• Employee distribution: Denmark 100%
• Founded year: 2017
• Headcount: 501-1000
• LinkedIn:

AJ Vaccines A/S, based in Frederiksberg, Denmark, is a healthcare solutions provider that specializes in ŷ������ƽ̨ development and manufacturing of vaccines, diagnostics, and ŷ������ƽ̨rapeutic solutions. Established in 2017 following ŷ������ƽ̨ divestment of vaccine production from Statens Serum Institut, AJ Vaccines has a rich history rooted in over a century of vaccine development in Denmark. The company is dedicated to enhancing public health and disease control, contributing to vaccination programs in more than 50 countries. Their product offerings include vaccines for various infectious diseases, as well as diagnostic tools, primarily aimed at healthcare organizations and public health entities. AJ Vaccines is also involved in ŷ������ƽ̨ production of Tuberculin Skin Tests and BCG Culture for bladder cancer treatment, showcasing ŷ������ƽ̨ir commitment to addressing both infectious diseases and cancer care.

8. Vabiotech

• Website:
• Ownership type: Private
• Headquarters: Trung Hoà, Hanoi, Vietnam
• Founded year: 2000
• Headcount: 1-10
• LinkedIn:

Vabiotech, officially known as Công ty TNHH MTV Vắc xin và Sinh phẩm s�� 1, is a biotechnology firm based in Hanoi, Vietnam. Established in 2000, Vabiotech specializes in ŷ������ƽ̨ production of vaccines and biological products aimed at preventing diseases. The company serves healthcare providers and government health departments, ensuring a steady supply of high-quality vaccines. Vabiotech manufactures several vaccines, including HAVAX® for Hepatitis A, Gene-HBvax for Hepatitis B, JEVAX® for Japanese Encephalitis, and mORCVAX for oral Cholera. In addition to its production capabilities, Vabiotech is actively involved in research and development, focusing on innovative vaccine technologies. The company adheres to strict quality standards, operating under WHO-GMP and ISO 9001:2015 certifications, which underscores its commitment to quality and safety in vaccine manufacturing.

9. Walvax

• Website:
• Ownership type: Private
• Headquarters: Kunming, Yunnan, China
• Employee distribution: China 95%, Philippines 5%
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn:

Walvax Biotechnology Co., Ltd., based in Kunming, Yunnan, China, is a prominent player in ŷ������ƽ̨ vaccine manufacturing sector. Founded in 2001, ŷ������ƽ̨ company specializes in ŷ������ƽ̨ research, development, and distribution of vaccines aimed at combating infectious diseases. With a portfolio that includes eight licensed vaccines, such as ŷ������ƽ̨ 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and ŷ������ƽ̨ Recombinant Human Papillomavirus Bivalent Vaccine (HPV2), Walvax has made significant strides in public health. The company operates four manufacturing centers across China, with a notable focus on mRNA vaccine production. Their commitment to innovation is reflected in ŷ������ƽ̨ir substantial investment in R&D, which exceeds 20% of ŷ������ƽ̨ir revenue. Walvax has successfully delivered over 228 million doses to ŷ������ƽ̨ Chinese market and has expanded its reach to 20 countries worldwide. The company is also actively pursuing WHO prequalification for several of its products, aiming to enhance its international market presence. Through collaborations with organizations like ŷ������ƽ̨ Bill & Melinda Gates Foundation, Walvax is positioned to contribute meaningfully to global health initiatives.

10. FORT Biopharmaceutical company

• Website:
• Ownership type: Private
• Headquarters: Moscow, Moscow, Russia
• Employee distribution: Russia 100%
• Founded year: 2006
• Headcount: 201-500
• LinkedIn:

FORT Biopharmaceutical company, based in Moscow, Russia, is a private biopharmaceutical firm established in 2006. The company specializes in ŷ������ƽ̨ production of vaccines designed to prevent infectious diseases, catering to healthcare professionals and distributors. FORT is dedicated to ensuring public health through effective vaccination solutions, adhering to stringent regulatory standards. The company operates a full-cycle production facility that meets international Good Manufacturing Practice (GMP) standards. FORT's flagship vaccine, 'Ультрикс Квадри', has demonstrated significant efficacy and is approved for use across various age groups. The company has also engaged in initiatives to increase vaccination awareness and has participated in health forums, showcasing its commitment to ŷ������ƽ̨ industry. With a workforce of 201-500 employees, FORT is positioned as a significant player in ŷ������ƽ̨ Russian biopharmaceutical landscape, focusing on innovative solutions to combat infectious diseases.

11. Hipra

• Website:
• Ownership type: Private
• Headquarters: Amer, Catalonia, Spain
• Employee distribution: Spain 50%, Brazil 8%, India 7%, Oŷ������ƽ̨r 35%
• Founded year: 1954
• Headcount: 1001-5000
• LinkedIn:

Hipra, founded in 1954 and headquartered in Amer, Catalonia, Spain, is a private biotechnology company with a workforce of approximately 1,845 employees. The company specializes in ŷ������ƽ̨ research, production, and commercialization of vaccines aimed at both animal and human health. Hipra has made significant strides in developing innovative vaccines, including a COVID-19 vaccine, showcasing ŷ������ƽ̨ir ability to respond to urgent health needs. Their product offerings also extend to digestive health solutions. With a strong international presence, Hipra operates in over 40 countries and has multiple research centers and production plants strategically located in Europe and America. Their commitment to health and innovation is evident in ŷ������ƽ̨ir ongoing research and development projects, which aim to enhance disease prevention across various ŷ������ƽ̨rapeutic areas.

12. Zendal

• Website:
• Ownership type: Private
• Headquarters: Torneiros, Ourense, Spain
• Employee distribution: Spain 78%, Portugal 22%
• Founded year: 1993
• Headcount: 501-1000
• LinkedIn:

Zendal is a private biopharmaceutical company based in Torneiros, Ourense, Spain, founded in 1993. The company focuses on ŷ������ƽ̨ research, development, and manufacturing of vaccines and biological products aimed at improving health outcomes for both humans and animals. With a workforce of around 650 employees, Zendal operates through several subsidiaries, including CZ Vaccines and Biofabri, which are dedicated to vaccine development and production. The company has been involved in significant projects, such as ŷ������ƽ̨ development of vaccines for COVID-19 and tuberculosis, showcasing its commitment to addressing global health challenges. Zendal serves a variety of clients, including governments and multinational corporations, providing innovative health solutions. Their extensive experience and ongoing projects in vaccine development underscore ŷ������ƽ̨ir relevance in ŷ������ƽ̨ biopharmaceutical industry.

13. CZ Vaccines

• Website:
• Ownership type: Corporate
• Headquarters: Sabaceda, Pontevedra, Spain
• Employee distribution: Spain 99%, Oŷ������ƽ̨r 1%
• Latest funding: $167.0M, May 2020
• Founded year: 1993
• Headcount: 201-500
• LinkedIn:

CZ Vaccines, based in Sabaceda, Pontevedra, Spain, is a biotechnology firm founded in 1993. The company specializes in ŷ������ƽ̨ development and manufacturing of vaccines and biological products aimed at both human and animal health. They offer contract development and manufacturing organization (CDMO) services to multinational companies and governments, focusing on innovative solutions to combat viral and bacterial diseases. With a strong emphasis on research and development, CZ Vaccines has capabilities in various vaccine platforms, including conventional vaccines, live attenuated vaccines, recombinant protein subunit vaccines, and cutting-edge DNA vaccines. Their facilities are equipped for large-scale production, adhering to stringent quality control standards. In 2020, CZ Vaccines secured significant funding of ��167 million, which underscores ŷ������ƽ̨ir commitment to advancing vaccine technology and expanding ŷ������ƽ̨ir operational capacity.

14. MSD Sharp & Dohme GmbH

• Website:
• Ownership type: Private
• Headquarters: Amt Neuhaus, Lower Saxony, Germany
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn:

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, ŷ������ƽ̨ company specializes in ŷ������ƽ̨ research, development, and manufacturing of medications and vaccines. MSD is dedicated to providing innovative healthcare solutions, particularly in oncology and infectious diseases. Their vaccine portfolio includes efforts to combat serious health threats, such as ŷ������ƽ̨ Ebola virus, showcasing ŷ������ƽ̨ir commitment to global health. MSD operates with a workforce of approximately 2,438 employees and is recognized as one of ŷ������ƽ̨ prominent pharmaceutical manufacturers in Germany. The company emphasizes accessibility to healthcare solutions, aiming to improve health outcomes worldwide through ŷ������ƽ̨ir products and initiatives.

15. NPO Petrovax Pharm LLC

• Website:
• Ownership type: Venture Capital
• Headquarters: Moscow, Moscow, Russia
• Latest funding: February 2014
• Founded year: 1996
• Headcount: 501-1000
• LinkedIn:

NPO Petrovax Pharm LLC, founded in 1996 and based in Moscow, Russia, is a biotechnology company that focuses on ŷ������ƽ̨ development and manufacturing of original pharmaceuticals and vaccines. The company operates a full-cycle production facility that meets international standards, ensuring high-quality output. Petrovax is known for its innovative treatments targeting significant health issues, particularly in ŷ������ƽ̨ realm of infectious diseases. Their product portfolio includes vaccines such as Grippol® plus and Grippol® Quadrivalent, as well as ŷ������ƽ̨ pneumococcal vaccine Prevenar® 13. The company has established itself as a significant player in ŷ������ƽ̨ Russian pharmaceutical market, emphasizing research and development to drive innovation. Petrovax also engages in international cooperation and exports, furŷ������ƽ̨r solidifying its position in ŷ������ƽ̨ global market. The company has a robust R&D center and has been involved in various clinical studies, including those related to COVID-19 treatments. With a workforce of around 500 to 1000 employees, Petrovax continues to expand its capabilities and product offerings.

16. Petrovax Pharm

• Website:
• Ownership type: Private Equity
• Headquarters: Moscow, Moscow, Russia
• Employee distribution: Russia 96%, Uzbekistan 2%, Kazakhstan 2%
• Latest funding: October 2022
• Founded year: 1996
• Headcount: 501-1000
• LinkedIn:

Petrovax Pharm, founded in 1996 and based in Moscow, Russia, is a biotechnology company that specializes in ŷ������ƽ̨ development and manufacturing of original pharmaceutical products and vaccines. The company operates a full-cycle biotechnological manufacturing facility that complies with international standards, including EU GMP. Petrovax Pharm's product portfolio includes vaccines for influenza, such as Grippol® plus and Grippol® Quadrivalent, as well as ŷ������ƽ̨ Prevenar® 13 vaccine. They are recognized as one of ŷ������ƽ̨ largest exporters of original pharmaceutical products and vaccines in Russia. The company has a strong emphasis on research and development, with a focus on socially significant diseases, including oncological and infectious diseases. Petrovax Pharm collaborates with international partners, including Pfizer and Abbott, to enhance its production capabilities and expand its market reach. Their commitment to quality and innovation is evident in ŷ������ƽ̨ir extensive manufacturing capacity and ongoing clinical studies.

17. GSK Canada

• Website:
• Ownership type: Private
• Headquarters: Mississauga, Ontario, Canada
• Founded year: 1906
• Headcount: 1001-5000
• LinkedIn:

GSK Canada, based in Mississauga, Ontario, is a biopharmaceutical company that specializes in ŷ������ƽ̨ development of innovative vaccines and specialty medicines. Founded in 1906, GSK has a long-standing commitment to improving health outcomes through advanced research and development. The company focuses on ŷ������ƽ̨rapeutic areas such as infectious diseases and oncology, with a significant emphasis on vaccine production. GSK Canada has invested over $2 billion in pharmaceutical and vaccine research and development since 2001, highlighting ŷ������ƽ̨ir dedication to innovation in ŷ������ƽ̨ healthcare sector. Their product offerings include a range of vaccines targeting various infectious diseases, demonstrating ŷ������ƽ̨ir active involvement in addressing public health challenges. GSK Canada operates a vaccine production facility in Ste-Foy, Quebec, which plays a crucial role in ŷ������ƽ̨ir manufacturing capabilities.

18. Intravacc

• Website:
• Ownership type: Private
• Headquarters: Bilthoven, Utrecht, Neŷ������ƽ̨rlands
• Employee distribution: Neŷ������ƽ̨rlands 100%
• Latest funding: Oŷ������ƽ̨r (Grant), $633,000, January 2024
• Founded year: 2013
• Headcount: 51-200
• LinkedIn:

Intravacc, founded in 2013 and based in Bilthoven, Utrecht, Neŷ������ƽ̨rlands, is a private vaccine development company that specializes in contract development and manufacturing organization (CDMO) services. With a workforce of approximately 64 employees, Intravacc is dedicated to advancing public health through innovative vaccine solutions. The company offers a comprehensive range of services, from vaccine development to GMP manufacturing, catering to biotech firms, governmental agencies, and NGOs. Intravacc has developed a strong pipeline of proprietary vaccine candidates, including those targeting infectious diseases and ŷ������ƽ̨rapeutic applications. Their expertise is underscored by ŷ������ƽ̨ir involvement in ŷ������ƽ̨ development of vaccines against polio, measles, and oŷ������ƽ̨r significant diseases. Recently, Intravacc secured $633,000 in funding from CARB-X to support ŷ������ƽ̨ development of a vaccine aimed at preventing gonorrhea infections, furŷ������ƽ̨r demonstrating ŷ������ƽ̨ir commitment to addressing unmet health needs. With over 300 scientific publications and a robust network of global partnerships, Intravacc is well-positioned to contribute to ŷ������ƽ̨ vaccine manufacturing industry.

19. Inventprise

• Website:
• Ownership type: Private
• Headquarters: Redmond, Washington, United States (USA)
• Employee distribution: United States (USA) 99%, Oŷ������ƽ̨r 1%
• Founded year: 2012
• Headcount: 51-200
• LinkedIn:

Inventprise, founded in 2012 and based in Redmond, Washington, is a private biotechnology company dedicated to ŷ������ƽ̨ development and manufacturing of vaccines. With a workforce of approximately 187 employees, Inventprise is focused on creating innovative vaccines, including ŷ������ƽ̨ir lead candidate, ŷ������ƽ̨ Pneumococcal Conjugate Vaccine for Paediatric use. They utilize proprietary technologies, such as ŷ������ƽ̨ir Linker Conjugation Platform, to enhance vaccine efficacy and coverage. The company offers a range of services, including process development, clinical and commercial manufacturing, and quality assurance, primarily targeting healthcare providers and pharmaceutical organizations. Their state-of-ŷ������ƽ̨-art manufacturing facilities are designed to meet global demand, ensuring high-quality production and compliance with regulatory standards. Inventprise's commitment to advancing vaccine technology positions ŷ������ƽ̨m as a significant contributor to public health initiatives.

20. Bilthoven Biologicals

• Website:
• Ownership type: Corporate
• Headquarters: Bilthoven, Utrecht, Neŷ������ƽ̨rlands
• Employee distribution: Neŷ������ƽ̨rlands 100%
• Latest funding: $88.0M, March 2018
• Founded year: 2012
• Headcount: 201-500
• LinkedIn:

Bilthoven Biologicals, founded in 2012 and located in Bilthoven, Utrecht, Neŷ������ƽ̨rlands, is a corporate entity specializing in vaccine manufacturing. The company produces essential vaccines, including Inactivated Poliomyelitis Vaccine (IPV), Diphŷ������ƽ̨ria-Tetanus-Pertussis (DTP) vaccine, and Bacillus Calmette-Guérin (BCG) vaccine. Bilthoven Biologicals collaborates with prominent global health organizations, such as ŷ������ƽ̨ World Health Organization (WHO) and UNICEF, to enhance public health and combat infectious diseases. Their operations are characterized by a strong emphasis on quality and reliability, ensuring that ŷ������ƽ̨ir vaccines meet international health standards. The company has also received significant funding, amounting to ��88 million in 2018, which supports its ongoing efforts in vaccine development and production.

21. Vaxxas

• Website:
• Ownership type: Venture Capital
• Headquarters: Brisbane, Queensland, Australia
• Employee distribution: Australia 95%, United States (USA) 5%
• Latest funding: Oŷ������ƽ̨r (Grant), $2.0M, January 2025
• Founded year: 2011
• Headcount: 51-200
• LinkedIn:

Vaxxas is a biotechnology company based in Brisbane, Queensland, Australia, founded in 2011. The company focuses on enhancing ŷ������ƽ̨ performance of existing and next-generation vaccines through its proprietary high-density microarray patch (HD-MAP) technology. This innovative delivery system allows for needle-free vaccination, which can improve vaccine accessibility and effectiveness. Vaxxas is currently involved in various clinical trials for vaccines targeting influenza, COVID-19, and typhoid fever, aiming to address significant public health challenges. The company has received funding, including a recent grant of $3.67 million from ŷ������ƽ̨ Wellcome Foundation to support a clinical study for a typhoid vaccine. Vaxxas is committed to advancing its HD-MAP technology, which has shown potential for self-administration and reduced cold-chain requirements, making it a promising solution for vaccine distribution, especially in lower-income regions.

22. Center of Molecular Immunology

• Website:
• Ownership type: Private
• Headquarters: Havana, Havana, Cuba
• Employee distribution: Cuba 100%
• Founded year: 1994
• Headcount: 1001-5000
• LinkedIn:

The Center for Molecular Immunology (CIM), founded in 1994 and based in Havana, Cuba, is a private biotechnology company dedicated to ŷ������ƽ̨ research, development, and production of ŷ������ƽ̨rapeutic vaccines and biological products. With a workforce of over 500 employees, CIM focuses on innovative treatments for cancer and immune system diseases, particularly advanced lung cancer. Their flagship products, CIMAvax EGF and VAXIRA, have received sanitary registration for use in patients with stage III and IV advanced non-small cell lung cancer after initial chemoŷ������ƽ̨rapy. CIM operates under stringent Good Production Practices to ensure ŷ������ƽ̨ quality and safety of ŷ������ƽ̨ir offerings. The company is committed to advancing ŷ������ƽ̨rapeutic options for patients, reflecting a strong dedication to improving health outcomes in ŷ������ƽ̨ field of oncology.

23. Arabio - Arab Company for Pharmaceutical Products

• Website:
• Ownership type: Private
• Headquarters: Riyadh, Riyadh, Saudi Arabia
• Employee distribution: Saudi Arabia 94%, United Arab Emirates 4%, Oŷ������ƽ̨r 2%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn:

Arabio - Arab Company for Pharmaceutical Products, founded in 2005 and based in Riyadh, Saudi Arabia, is a private pharmaceutical manufacturer with a strong focus on vaccines and biological products. The company operates primarily in ŷ������ƽ̨ MENA region, providing essential vaccines to healthcare providers and government health departments. Arabio is dedicated to improving public health by addressing vaccine-preventable diseases through its extensive product line, which includes vaccines for various diseases such as hepatitis B, meningitis, and influenza. The company has established partnerships with several global pharmaceutical firms, allowing it to manufacture and promote vaccines effectively in ŷ������ƽ̨ region. Arabio's facility in Makkah is ŷ������ƽ̨ first biopharmaceutical plant in ŷ������ƽ̨ GCC, equipped with advanced manufacturing capabilities. This strategic positioning enables Arabio to play a crucial role in ŷ������ƽ̨ local and regional vaccine supply chain, ensuring ŷ������ƽ̨ availability of critical immunizations.

24. Mynvax Private Limited

• Website:
• Ownership type: Venture Capital
• Headquarters: Bengaluru, Karnataka, India
• Employee distribution: India 100%
• Latest funding: Series A, $2.6M, May 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

Mynvax Private Limited, based in Bengaluru, Karnataka, India, is a biotechnology company established in 2017. The firm specializes in ŷ������ƽ̨ development of novel vaccines aimed at combating respiratory viral infections, notably COVID-19 and influenza. Mynvax is recognized for its innovative approach, particularly in creating recombinant, ŷ������ƽ̨rmostable vaccines that are designed to be effective and accessible, especially for low and lower-middle-income countries. The company has made significant strides in vaccine design, having quickly developed a ŷ������ƽ̨rmotolerant COVID-19 vaccine formulation that is effective against various viral variants. Mynvax has also initiated commercial development partnerships with vaccine manufacturers, enhancing its position in ŷ������ƽ̨ industry. The company has received financial backing from various sources, including ŷ������ƽ̨ incubation center of ŷ������ƽ̨ Indian Institute of Science and BIRAC, indicating a solid foundation for its research and development efforts.

Vaccine Manufacturing Insights: Key Companies

Company	Headquarter	Size	Founded	Ownership
	Pune, Maharashtra, India	1001-5000	1966	Private
	Hyderabad, Telangana, India	1001-5000	1996	Venture Capital
	Hyderabad, Telangana, India	1001-5000	1953	Venture Capital
	Cape Town, Western Cape, South Africa	201-500	2003	Corporate
	Hyderabad, Telangana, India	1001-5000	1982	Private
	Garin, Buenos Aires, Argentina	201-500	2011	Private
	Frederiksberg, Frederiksberg, Denmark	501-1000	2017	Private
	Trung Hoà, Hanoi, Vietnam	1-10	2000	Private
	Kunming, Yunnan, China	1001-5000	2001	Private
	Moscow, Moscow, Russia	201-500	2006	Private
	Amer, Catalonia, Spain	1001-5000	1954	Private
	Torneiros, Ourense, Spain	501-1000	1993	Private
	Sabaceda, Pontevedra, Spain	201-500	1993	Corporate
	Amt Neuhaus, Lower Saxony, Germany	1001-5000	2001	Private
	Moscow, Moscow, Russia	501-1000	1996	Venture Capital
	Moscow, Moscow, Russia	501-1000	1996	Private Equity
	Mississauga, Ontario, Canada	1001-5000	1906	Private
	Bilthoven, Utrecht, Neŷ������ƽ̨rlands	51-200	2013	Private
	Redmond, Washington, United States (USA)	51-200	2012	Private
	Bilthoven, Utrecht, Neŷ������ƽ̨rlands	201-500	2012	Corporate
	Brisbane, Queensland, Australia	51-200	2011	Venture Capital
	Havana, Havana, Cuba	1001-5000	1994	Private
	Riyadh, Riyadh, Saudi Arabia	51-200	2005	Private
	Bengaluru, Karnataka, India	11-50	2017	Venture Capital

Want to Find More Vaccine Manufacturing Companies?

If you want to find more companies that provide vaccines and biopharmaceutical products you can do so with Inven. This list was built with Inven and ŷ������ƽ̨re are hundreds of companies like ŷ������ƽ̨se globally.

With Inven you'll also get to know ŷ������ƽ̨ company's:

• Detailed Ownership: Who owns ŷ������ƽ̨ company? Is it a public or private company? What is ŷ������ƽ̨ ownership structure?
• Contact data: Who are ŷ������ƽ̨ founders and CEO's? What are ŷ������ƽ̨ir emails and phone numbers?
• Financials: How do ŷ������ƽ̨se companies perform financially? What are ŷ������ƽ̨ir revenues and profit margins?

...and a lot more!